PubRank

H Ballentine Carter

Author PubWeight™ 143.38‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Complications after prostate biopsy: data from SEER-Medicare. J Urol 2011 5.40
2 Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011 5.27
3 Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol 2012 4.24
4 African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? J Clin Oncol 2013 4.20
5 Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 2010 4.17
6 Is repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare. J Urol 2012 4.11
7 Prostate specific antigen best practice statement: 2009 update. J Urol 2009 3.95
8 Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst 2006 2.96
9 Baseline prostate-specific antigen testing at a young age. Eur Urol 2011 2.95
10 Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance. J Urol 2013 2.66
11 What is the true number needed to screen and treat to save a life with prostate-specific antigen testing? J Clin Oncol 2010 2.49
12 Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Urol 2009 2.41
13 Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 2008 2.33
14 NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw 2010 2.31
15 Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 2006 2.17
16 Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol 2009 2.17
17 Should prostate specific antigen be adjusted for body mass index? Data from the Baltimore Longitudinal Study of Aging. J Urol 2009 2.09
18 Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2007 2.06
19 Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur Urol 2007 2.02
20 Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol 2004 1.85
21 Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer. J Urol 2012 1.80
22 PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging. Eur Urol 2008 1.78
23 Indications for intervention during active surveillance of prostate cancer: a comparison of the Johns Hopkins and Prostate Cancer Research International Active Surveillance (PRIAS) protocols. BJU Int 2014 1.73
24 ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program. Urology 2011 1.71
25 Prostate specific antigen testing among the elderly--when to stop? J Urol 2009 1.62
26 Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging. BJU Int 2009 1.59
27 Geometric evaluation of systematic transrectal ultrasound guided prostate biopsy. J Urol 2012 1.59
28 Disparities in treatment and outcome for renal cell cancer among older black and white patients. J Clin Oncol 2007 1.56
29 Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev 2005 1.55
30 Multiparametric magnetic resonance imaging findings in men with low-risk prostate cancer followed using active surveillance. BJU Int 2013 1.55
31 Low prostate-specific antigen and no Gleason score upgrade despite more extensive cancer during active surveillance predicts insignificant prostate cancer at radical prostatectomy. Urology 2012 1.54
32 Active surveillance versus surgery for low risk prostate cancer: a clinical decision analysis. J Urol 2012 1.54
33 Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing. J Urol 2013 1.53
34 Prostate cancers in men with low PSA levels--must we find them? N Engl J Med 2004 1.52
35 Radical retropubic prostatectomy. How often do experienced surgeons have positive surgical margins when there is extraprostatic extension in the region of the neurovascular bundle? J Urol 2005 1.52
36 Distribution of PSA velocity by total PSA levels: data from the Baltimore Longitudinal Study of Aging. Urology 2011 1.51
37 Risk stratification of men choosing surveillance for low risk prostate cancer. J Urol 2010 1.47
38 Anatomic extent of pelvic lymph node dissection: impact on long-term cancer-specific outcomes in men with positive lymph nodes at time of radical prostatectomy. Urology 2013 1.47
39 Calcium intake and prostate cancer risk in a long-term aging study: the Baltimore Longitudinal Study of Aging. Urology 2002 1.46
40 Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy. Urology 2005 1.46
41 Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer. BJU Int 2012 1.44
42 Efficacy of periprostatic local anesthetic for prostate biopsy analgesia: a meta-analysis. Urology 2006 1.40
43 Change in prostate cancer grade over time in men followed expectantly for stage T1c disease. J Urol 2008 1.30
44 Expanded criteria to identify men eligible for active surveillance of low risk prostate cancer at Johns Hopkins: a preliminary analysis. J Urol 2013 1.30
45 Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer. Clin Cancer Res 2009 1.26
46 Prostate cancer mortality following active surveillance versus immediate radical prostatectomy. Clin Cancer Res 2012 1.25
47 The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: consensus statement with recommendations supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the Prostate Cancer Foundation. Arch Pathol Lab Med 2014 1.17
48 Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol Biomarkers Prev 2005 1.13
49 Primary care providers' response to the US Preventive Services Task Force draft recommendations on screening for prostate cancer. Arch Intern Med 2012 1.08
50 Single nucleotide polymorphisms and the likelihood of prostate cancer at a given prostate specific antigen level. J Urol 2009 1.08
51 Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? J Urol 2003 1.03
52 Prostate specific antigen best practice statement: 2009 update. J Urol 2013 1.03
53 Improved biomarkers for prostate cancer: a definite need. J Natl Cancer Inst 2004 1.02
54 Prostate volume changes over time: results from the Baltimore Longitudinal Study of Aging. J Urol 2009 1.00
55 Association of quantitative magnetic resonance imaging parameters with histological findings from MRI/ultrasound fusion prostate biopsy. Can J Urol 2015 0.98
56 Association of prostate cancer risk with insulin, glucose, and anthropometry in the Baltimore longitudinal study of aging. Urology 2004 0.98
57 Serum prostate-specific antigen (PSA) concentration is positively associated with rate of disease reclassification on subsequent active surveillance prostate biopsy in men with low PSA density. BJU Int 2013 0.96
58 Point: Impact of prostate-specific antigen velocity on management decisions and recommendations. J Natl Compr Canc Netw 2013 0.96
59 Estimation of treatment benefits when PSA screening for prostate cancer is discontinued at different ages. Urology 2005 0.95
60 Expectant treatment with curative intent in the prostate-specific antigen era: triggers for definitive therapy. Urol Oncol 2006 0.94
61 Primary care providers' perspectives on discontinuing prostate cancer screening. Cancer 2012 0.92
62 Effect of intra-observer variation in prostate volume measurement on prostate-specific antigen density calculations among prostate cancer active surveillance participants. BJU Int 2011 0.92
63 Obesity does not adversely affect health-related quality-of-life outcomes after anatomic retropubic radical prostatectomy. Urology 2005 0.91
64 Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy. J Urol 2007 0.90
65 DNA content in the diagnostic biopsy for benign-adjacent and cancer-tissue areas predicts the need for treatment in men with T1c prostate cancer undergoing surveillance in an expectant management programme. BJU Int 2009 0.90
66 Update on watchful waiting for prostate cancer. Curr Opin Urol 2004 0.89
67 Multiparametric magnetic resonance imaging characterization of prostate lesions in the active surveillance population: incremental value of magnetic resonance imaging for prediction of disease reclassification. J Comput Assist Tomogr 2013 0.87
68 Radical prostatectomy outcome in men 65 years old or older with low risk prostate cancer. J Urol 2012 0.87
69 Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intent. Prostate 2008 0.86
70 Association of energy intake with prostate cancer in a long-term aging study: Baltimore Longitudinal Study of Aging (United States). Urology 2003 0.85
71 Interpretation of the prostate-specific antigen history in assessing life-threatening prostate cancer. BJU Int 2010 0.83
72 Informed consent for prostate-specific antigen screening. Urology 2003 0.83
73 Significance of prostate adenocarcinoma perineural invasion on biopsy in patients who are otherwise candidates for active surveillance. J Urol 2011 0.83
74 Characteristics and experiences of patients with localized prostate cancer who left an active surveillance program. Patient 2014 0.83
75 Update on PSA testing. J Natl Compr Canc Netw 2007 0.83
76 Prostate-specific antigen and all-cause mortality: results from the Baltimore Longitudinal Study On Aging. J Natl Cancer Inst 2004 0.82
77 Use of spinal anesthesia does not reduce intraoperative blood loss. Urology 2007 0.81
78 Prostate volumetric assessment by magnetic resonance imaging and transrectal ultrasound: impact of variation in calculated prostate-specific antigen density on patient eligibility for active surveillance program. J Comput Assist Tomogr 2013 0.80
79 Does prostate growth confound prostate specific antigen velocity? Data from the Baltimore longitudinal study of aging. J Urol 2008 0.80
80 Re: an empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst 2011 0.80
81 Repeat prostate biopsies predict location of index cancer in an active surveillance cohort. BJU Int 2011 0.80
82 The relationship between prostate volume and prostate-specific antigen variability: data from the Baltimore Longitudinal Study of Aging and the Johns Hopkins Active Surveillance Program. BJU Int 2011 0.79
83 PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml. Urology 2002 0.79
84 The discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostate. J Urol 2006 0.79
85 Health-related quality-of-life outcomes after anatomic retropubic radical prostatectomy in the phosphodiesterase type 5 ERA: impact of neurovascular bundle preservation. Urology 2005 0.78
86 The importance of pelvic lymph node dissection in men with clinically localized prostate cancer. Rev Urol 2006 0.78
87 Multiparametric magnetic resonance imaging (MRI) and active surveillance for prostate cancer: future directions. BJU Int 2014 0.78
88 Spinal anesthesia does not impact prostate cancer recurrence in a cohort of men undergoing radical prostatectomy: an observational study. Reg Anesth Pain Med 2014 0.77
89 Assessing risk: does this patient have prostate cancer? J Natl Cancer Inst 2006 0.77
90 Eleventh Prouts Neck Meeting on Prostate Cancer: emerging strategies in prostate cancer therapy. Cancer Res 2007 0.77
91 Editorial comment. Urology 2009 0.75
92 Re: long-term followup after laparoscopic radical nephrectomy. J Urol 2002 0.75
93 Should prostate-specific antigen velocity be abandoned? Asian J Androl 2011 0.75
94 Editorial comment. J Urol 2012 0.75
95 Words of wisdom. Re: Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. Eur Urol 2009 0.75
96 Editorial comment. J Urol 2010 0.75
97 Bone mineral content and prostate cancer risk: data from the Baltimore Longitudinal Study of Aging. BJU Int 2010 0.75
98 Continued undertreatment of older men with localized prostate cancer. Urology 2004 0.75
99 Baseline PSA testing for men in their 40s: testing in average-risk men aged 40 to 50 years should not be routinely performed. Oncology (Williston Park) 2014 0.75
100 Investigation of human anti-mouse antibodies as potential cause of postprostatectomy PSA elevation. Urology 2009 0.75
101 A clinicopathologic study of preoperative and postoperative findings with minute Gleason 3+3=6 cancer at radical prostatectomy. Urology 2008 0.75
102 Limitations and use of PSA derivatives in the screening and risk stratification of prostate cancer. Urol Oncol 2009 0.75
103 Helping to address the over treatment of prostate cancer: tools to differentiate lethal and non-lethal phenotype in prostate cancer. Asian J Androl 2012 0.75
104 Expectant management of localized prostate cancer. Urology 2003 0.75
105 Prediagnostic plasma vitamin C levels and the subsequent risk of prostate cancer. Nutrition 2005 0.75
106 Consultation corner. Prostate screening: refining what PSA levels mean. Johns Hopkins Med Lett Health After 50 2007 0.75
107 PSA scores: should we use a lower threshold? Johns Hopkins Med Lett Health After 50 2004 0.75
108 Prostate cancer in patients with the bladder exstrophy-epispadias complex: insights and outcomes. Urology 2008 0.75